 Suchitra Rao
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 31 | 2025 | 601 | 10.110 |
Why?
| | Influenza Vaccines | 16 | 2025 | 532 | 4.590 |
Why?
| | Vaccination | 20 | 2025 | 1348 | 2.880 |
Why?
| | Respiratory Syncytial Virus Infections | 4 | 2024 | 120 | 2.420 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2024 | 69 | 2.370 |
Why?
| | Respiratory Tract Infections | 5 | 2023 | 376 | 2.340 |
Why?
| | Hospitalization | 31 | 2025 | 2070 | 2.060 |
Why?
| | Systemic Inflammatory Response Syndrome | 3 | 2024 | 85 | 1.710 |
Why?
| | Influenza A Virus, H1N1 Subtype | 5 | 2024 | 146 | 1.600 |
Why?
| | Emergency Service, Hospital | 18 | 2025 | 1902 | 1.590 |
Why?
| | Child | 55 | 2025 | 20883 | 1.480 |
Why?
| | Child, Preschool | 37 | 2025 | 10517 | 1.390 |
Why?
| | Infant | 27 | 2025 | 9024 | 1.310 |
Why?
| | Antiviral Agents | 7 | 2025 | 712 | 1.060 |
Why?
| | Retrospective Studies | 28 | 2025 | 14518 | 1.050 |
Why?
| | Coinfection | 2 | 2022 | 131 | 1.050 |
Why?
| | Absenteeism | 2 | 2024 | 47 | 1.040 |
Why?
| | Connective Tissue Diseases | 2 | 2023 | 82 | 1.010 |
Why?
| | Influenza A Virus, H3N2 Subtype | 5 | 2024 | 43 | 1.000 |
Why?
| | Polyomavirus Infections | 3 | 2016 | 28 | 0.960 |
Why?
| | Humans | 97 | 2025 | 129650 | 0.930 |
Why?
| | Polyomavirus | 3 | 2016 | 13 | 0.910 |
Why?
| | Immunocompromised Host | 3 | 2021 | 198 | 0.900 |
Why?
| | Croup | 1 | 2024 | 26 | 0.900 |
Why?
| | Colorado | 12 | 2023 | 4421 | 0.850 |
Why?
| | Bronchiolitis | 1 | 2024 | 90 | 0.840 |
Why?
| | Ageusia | 1 | 2022 | 1 | 0.820 |
Why?
| | Immunization Programs | 1 | 2025 | 214 | 0.820 |
Why?
| | Seizures | 3 | 2024 | 402 | 0.800 |
Why?
| | Metapneumovirus | 1 | 2022 | 14 | 0.790 |
Why?
| | Adolescent | 42 | 2025 | 20393 | 0.760 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2021 | 203 | 0.750 |
Why?
| | Oseltamivir | 2 | 2025 | 11 | 0.750 |
Why?
| | Myocarditis | 1 | 2022 | 98 | 0.730 |
Why?
| | Viruses | 1 | 2022 | 100 | 0.730 |
Why?
| | Male | 47 | 2025 | 63681 | 0.680 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 98 | 0.680 |
Why?
| | Autoimmune Diseases | 1 | 2024 | 426 | 0.680 |
Why?
| | Endpoint Determination | 1 | 2020 | 76 | 0.670 |
Why?
| | Female | 47 | 2025 | 68776 | 0.640 |
Why?
| | Respiratory Tract Diseases | 2 | 2021 | 148 | 0.630 |
Why?
| | Birth Order | 1 | 2019 | 13 | 0.630 |
Why?
| | Advisory Committees | 1 | 2020 | 216 | 0.620 |
Why?
| | Streptococcal Infections | 1 | 2021 | 148 | 0.620 |
Why?
| | Onchocerciasis | 2 | 2015 | 7 | 0.610 |
Why?
| | Sinusitis | 1 | 2021 | 210 | 0.600 |
Why?
| | Encephalitis | 2 | 2017 | 133 | 0.590 |
Why?
| | Viral Load | 4 | 2024 | 448 | 0.550 |
Why?
| | Nervous System Diseases | 1 | 2020 | 252 | 0.540 |
Why?
| | Seasons | 7 | 2025 | 502 | 0.540 |
Why?
| | Medical Audit | 1 | 2016 | 77 | 0.510 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1717 | 0.510 |
Why?
| | United States | 29 | 2025 | 13903 | 0.510 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 352 | 0.500 |
Why?
| | Family Characteristics | 3 | 2025 | 179 | 0.480 |
Why?
| | Ambulatory Care | 7 | 2024 | 504 | 0.480 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 82 | 0.470 |
Why?
| | Spinal Cord Diseases | 1 | 2015 | 41 | 0.470 |
Why?
| | Cohort Studies | 11 | 2024 | 5420 | 0.470 |
Why?
| | Acyclovir | 1 | 2015 | 99 | 0.460 |
Why?
| | Case-Control Studies | 9 | 2023 | 3381 | 0.450 |
Why?
| | Attitude to Health | 1 | 2017 | 431 | 0.450 |
Why?
| | Enterovirus Infections | 1 | 2016 | 171 | 0.430 |
Why?
| | Ritonavir | 2 | 2024 | 73 | 0.430 |
Why?
| | Hospitals, Pediatric | 2 | 2025 | 509 | 0.430 |
Why?
| | Health Promotion | 1 | 2019 | 719 | 0.420 |
Why?
| | Infection Control | 1 | 2014 | 140 | 0.410 |
Why?
| | Electronic Health Records | 5 | 2025 | 975 | 0.400 |
Why?
| | Mothers | 1 | 2019 | 729 | 0.400 |
Why?
| | Cross Infection | 1 | 2014 | 218 | 0.390 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1706 | 0.390 |
Why?
| | Infant, Newborn | 9 | 2024 | 5762 | 0.380 |
Why?
| | Virus Diseases | 1 | 2014 | 211 | 0.380 |
Why?
| | Young Adult | 17 | 2025 | 12426 | 0.380 |
Why?
| | Health Personnel | 1 | 2017 | 652 | 0.370 |
Why?
| | Anticonvulsants | 2 | 2024 | 209 | 0.370 |
Why?
| | Adult | 32 | 2025 | 35576 | 0.370 |
Why?
| | Hematologic Diseases | 1 | 2011 | 61 | 0.360 |
Why?
| | Outpatients | 2 | 2024 | 370 | 0.340 |
Why?
| | Stomach Rupture | 1 | 2009 | 2 | 0.320 |
Why?
| | Liver Abscess, Amebic | 1 | 2009 | 3 | 0.320 |
Why?
| | Parents | 1 | 2017 | 1309 | 0.310 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.310 |
Why?
| | Pleural Effusion | 1 | 2009 | 51 | 0.300 |
Why?
| | Program Evaluation | 2 | 2025 | 875 | 0.300 |
Why?
| | Electroencephalography | 2 | 2024 | 403 | 0.300 |
Why?
| | Peritonitis | 1 | 2009 | 81 | 0.300 |
Why?
| | Pandemics | 3 | 2023 | 1488 | 0.280 |
Why?
| | Immunization, Secondary | 3 | 2022 | 87 | 0.280 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 790 | 0.270 |
Why?
| | Severity of Illness Index | 5 | 2025 | 2742 | 0.270 |
Why?
| | Motivation | 2 | 2022 | 546 | 0.260 |
Why?
| | Risk Factors | 8 | 2025 | 9765 | 0.260 |
Why?
| | Prospective Studies | 6 | 2025 | 7133 | 0.260 |
Why?
| | Body Mass Index | 3 | 2024 | 2273 | 0.260 |
Why?
| | Angiostrongylus cantonensis | 2 | 2018 | 3 | 0.260 |
Why?
| | Strongylida Infections | 2 | 2018 | 6 | 0.260 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1266 | 0.250 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 126 | 0.230 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 34 | 0.220 |
Why?
| | Virus Shedding | 1 | 2024 | 48 | 0.220 |
Why?
| | Disease Progression | 4 | 2024 | 2635 | 0.220 |
Why?
| | RNA, Messenger | 7 | 2024 | 2708 | 0.210 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 110 | 0.210 |
Why?
| | Antigens, Viral | 1 | 2024 | 178 | 0.210 |
Why?
| | Vaccines, Combined | 4 | 2023 | 48 | 0.210 |
Why?
| | Physicians | 2 | 2023 | 865 | 0.210 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2016 | 331 | 0.210 |
Why?
| | Child, Hospitalized | 1 | 2023 | 49 | 0.200 |
Why?
| | Propensity Score | 1 | 2024 | 265 | 0.200 |
Why?
| | Inpatients | 2 | 2017 | 467 | 0.200 |
Why?
| | Vital Signs | 1 | 2022 | 41 | 0.200 |
Why?
| | Middle Aged | 18 | 2025 | 31154 | 0.190 |
Why?
| | Viral Vaccines | 1 | 2023 | 94 | 0.190 |
Why?
| | Aged | 14 | 2025 | 22103 | 0.190 |
Why?
| | Cough | 1 | 2022 | 116 | 0.190 |
Why?
| | Patient Readmission | 2 | 2024 | 667 | 0.190 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.180 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 759 | 0.180 |
Why?
| | Guideline Adherence | 1 | 2025 | 526 | 0.180 |
Why?
| | Drug Utilization | 2 | 2024 | 171 | 0.170 |
Why?
| | Confusion | 1 | 2020 | 28 | 0.170 |
Why?
| | Encephalitis, Viral | 1 | 2020 | 43 | 0.160 |
Why?
| | Critical Pathways | 1 | 2020 | 80 | 0.160 |
Why?
| | Immunization Schedule | 2 | 2021 | 197 | 0.160 |
Why?
| | Antibodies, Viral | 2 | 2023 | 601 | 0.160 |
Why?
| | Length of Stay | 1 | 2024 | 1127 | 0.160 |
Why?
| | Brain Diseases | 1 | 2020 | 137 | 0.150 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 122 | 0.150 |
Why?
| | Information Dissemination | 1 | 2020 | 206 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 367 | 0.150 |
Why?
| | Oxygen | 1 | 2023 | 915 | 0.150 |
Why?
| | Infant, Small for Gestational Age | 1 | 2019 | 85 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 360 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 135 | 0.150 |
Why?
| | Interprofessional Relations | 1 | 2020 | 277 | 0.150 |
Why?
| | Reminder Systems | 1 | 2019 | 174 | 0.140 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 221 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 147 | 0.140 |
Why?
| | Anti-Infective Agents | 1 | 2020 | 248 | 0.140 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 68 | 0.140 |
Why?
| | Cost of Illness | 2 | 2016 | 278 | 0.140 |
Why?
| | Pneumonia | 2 | 2016 | 616 | 0.140 |
Why?
| | Disease Outbreaks | 2 | 2020 | 349 | 0.140 |
Why?
| | Nurses | 1 | 2019 | 164 | 0.140 |
Why?
| | Adiposity | 1 | 2022 | 504 | 0.130 |
Why?
| | Neoplasms | 1 | 2011 | 2470 | 0.130 |
Why?
| | Tertiary Healthcare | 1 | 2016 | 29 | 0.130 |
Why?
| | Philippines | 1 | 2016 | 49 | 0.130 |
Why?
| | Fatigue | 1 | 2018 | 318 | 0.130 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 65 | 0.130 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7086 | 0.130 |
Why?
| | Critical Care | 1 | 2021 | 553 | 0.130 |
Why?
| | Nasal Cavity | 1 | 2016 | 51 | 0.130 |
Why?
| | Onchocerca | 1 | 2015 | 3 | 0.130 |
Why?
| | Patient Discharge | 2 | 2019 | 857 | 0.130 |
Why?
| | Urban Population | 1 | 2019 | 441 | 0.130 |
Why?
| | Zoonoses | 1 | 2015 | 29 | 0.120 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 33 | 0.120 |
Why?
| | Catheterization, Peripheral | 1 | 2016 | 104 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1030 | 0.120 |
Why?
| | Dog Diseases | 1 | 2015 | 52 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.120 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 21 | 0.120 |
Why?
| | Rural Population | 1 | 2019 | 518 | 0.120 |
Why?
| | Time Factors | 4 | 2025 | 6556 | 0.120 |
Why?
| | Computational Biology | 1 | 2019 | 599 | 0.120 |
Why?
| | Incidence | 1 | 2021 | 2644 | 0.110 |
Why?
| | Hospitals | 3 | 2024 | 637 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 400 | 0.110 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 133 | 0.110 |
Why?
| | Pregnancy | 3 | 2022 | 6402 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 887 | 0.100 |
Why?
| | Survival Rate | 1 | 2017 | 1877 | 0.100 |
Why?
| | Quality Improvement | 1 | 2020 | 1103 | 0.100 |
Why?
| | Meningitis | 1 | 2013 | 80 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 1988 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 851 | 0.090 |
Why?
| | Registries | 1 | 2019 | 1896 | 0.090 |
Why?
| | Critical Illness | 1 | 2016 | 758 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 110 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1368 | 0.090 |
Why?
| | Eosinophilia | 1 | 2013 | 204 | 0.090 |
Why?
| | Internship and Residency | 1 | 2019 | 1053 | 0.080 |
Why?
| | Pediatrics | 1 | 2017 | 1052 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 2 | 0.080 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.080 |
Why?
| | DNA, Viral | 1 | 2011 | 350 | 0.080 |
Why?
| | Entamoeba histolytica | 1 | 2009 | 7 | 0.080 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 13 | 0.080 |
Why?
| | Metronidazole | 1 | 2009 | 20 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2023 | 850 | 0.080 |
Why?
| | Prevalence | 2 | 2025 | 2564 | 0.070 |
Why?
| | Drainage | 1 | 2009 | 165 | 0.070 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.070 |
Why?
| | Insect Bites and Stings | 1 | 2007 | 11 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 30 | 0.070 |
Why?
| | Plasmodium falciparum | 1 | 2007 | 29 | 0.070 |
Why?
| | Malaria, Falciparum | 1 | 2007 | 26 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2023 | 10230 | 0.070 |
Why?
| | Animals | 6 | 2018 | 35361 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3628 | 0.070 |
Why?
| | Viral Proteins | 1 | 2009 | 328 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 573 | 0.060 |
Why?
| | Contact Tracing | 1 | 2025 | 23 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5406 | 0.060 |
Why?
| | Basic Reproduction Number | 1 | 2025 | 5 | 0.060 |
Why?
| | Safety | 1 | 2007 | 331 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3408 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2679 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1434 | 0.060 |
Why?
| | Lopinavir | 1 | 2024 | 30 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2025 | 123 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 5 | 0.060 |
Why?
| | Genotype | 1 | 2009 | 1839 | 0.050 |
Why?
| | Pediatricians | 1 | 2025 | 129 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5066 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 330 | 0.050 |
Why?
| | Acetamides | 1 | 2023 | 36 | 0.050 |
Why?
| | Bradycardia | 1 | 2023 | 53 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2025 | 375 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2024 | 149 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 8 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 79 | 0.050 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 122 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 45 | 0.050 |
Why?
| | Diabetic Ketoacidosis | 1 | 2023 | 197 | 0.040 |
Why?
| | Obesity | 2 | 2024 | 2883 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1838 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2535 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2023 | 427 | 0.040 |
Why?
| | Machine Learning | 1 | 2023 | 443 | 0.040 |
Why?
| | Research Design | 1 | 2024 | 1044 | 0.040 |
Why?
| | Pediatric Obesity | 1 | 2024 | 572 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1501 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 439 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1214 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 738 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1269 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 18 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 141 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1547 | 0.030 |
Why?
| | Southwestern United States | 1 | 2015 | 91 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 340 | 0.030 |
Why?
| | Cats | 1 | 2015 | 208 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3240 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3076 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 381 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2717 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 786 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3144 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 17 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1622 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1038 | 0.020 |
Why?
| | Cross Reactions | 1 | 2009 | 132 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 156 | 0.020 |
Why?
| | Age Distribution | 1 | 2009 | 372 | 0.020 |
Why?
| | Parasitemia | 1 | 2007 | 11 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 833 | 0.020 |
Why?
|
|
Rao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|